Literature DB >> 6249835

The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing's disease and Nelson's syndrome.

S W Lamberts, J G Klijn, M de Quijada, H A Timmermans, P Uitterlinden, F H de Jong, J C Birkenhäger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6249835     DOI： 10.1210/jcem-51-2-307

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  21 in total

1.  Six year remission of ACTH-dependent Cushing's syndrome using bromocriptine.

Authors:  A B Atkinson; A L Kennedy; B Sheridan
Journal:  Postgrad Med J       Date:  1985-03       Impact factor: 2.401

Review 2.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

3.  Cushing's disease and marked hyperprolactinemia in a patient with a pituitary macroadenoma: effectiveness of bromocriptine treatment.

Authors:  G Verde; P Loli; M E Berselli; M Tagliaferri; D Dallabonzana; G Oppizzi; A Liuzzi; P G Chiodini; G Luccarelli; S Lodrini
Journal:  J Endocrinol Invest       Date:  1984-02       Impact factor: 4.256

4.  The state of the renin-angiotensin-aldosterone system in patients with the neuroendocrine-metabolic form of the hypothalamic syndrome.

Authors:  V N Slavnov; V V Markov; V M Rudichenko; E V Luchitskii; V A Oleinik
Journal:  Neurosci Behav Physiol       Date:  1993 May-Jun

5.  Long term bromocriptine therapy in Cushing's disease.

Authors:  L P Kapcala; I M Jackson
Journal:  J Endocrinol Invest       Date:  1982 Mar-Apr       Impact factor: 4.256

6.  Effect of short and long-term administration of lisuride in Cushing's disease.

Authors:  M Boscaro; G Merola; E Serafini; F Mantero
Journal:  J Endocrinol Invest       Date:  1985-02       Impact factor: 4.256

7.  Complete remission of Nelson's syndrome after 1-year treatment with cabergoline.

Authors:  R Pivonello; A Faggiano; F Di Salle; M Filippella; G Lombardi; A Colao
Journal:  J Endocrinol Invest       Date:  1999-12       Impact factor: 4.256

8.  Dopamine agonists and analogues have an antiproliferative effect on CHO-K1 cells.

Authors:  R Maggio; M Armogida; M Scarselli; F Salvadori; B Longoni; C Pardini; A Chiarenza; S Chiacchio; F Vaglini; R Bernardini; A Colzi; G U Corsini
Journal:  Neurotox Res       Date:  2000-04       Impact factor: 3.911

9.  Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease.

Authors:  Lucio Vilar; Luciana A Naves; Monalisa F Azevedo; Maria Juliana Arruda; Carla M Arahata; Lidiane Moura E Silva; Rodrigo Agra; Lisete Pontes; Larissa Montenegro; José Luciano Albuquerque; Viviane Canadas
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

10.  Bromocriptine inhibits pro-opiomelanocortin mRNA and ACTH precursor secretion in small cell lung cancer cell lines.

Authors:  W E Farrell; A J Clark; M F Stewart; S R Crosby; A White
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.